Brainomix Expands U.S. Lung AI Footprint Through Strategic Boehringer Ingelheim Partnership

New updates have been reported about Brainomix.

Brainomix is deepening its strategic alliance with Boehringer Ingelheim to scale deployment of its FDA-cleared e-Lung AI imaging platform for progressive pulmonary fibrosis, positioning the company to expand its U.S. clinical footprint and evidence base. Building on the retrospective REVISE-PPF study, which showed e-Lung could stratify patients at risk of progression from a baseline CT and detect radiologic signs of disease up to 28 months before local diagnoses, the partners will now move into a prospective, multicenter phase.

The new PROGRESS-PPF study will install e-Lung across multiple U.S. sites to generate quantitative and qualitative real-world data on its impact when used routinely, with the goal of demonstrating earlier diagnosis, earlier treatment decisions, and improved outcomes in interstitial lung disease. Brainomix executives describe this phase as critical for validating e-Lung at scale and for reinforcing the company’s position as a leading AI player in lung fibrosis, supported by high-profile exposure at the American Thoracic Society conference, where REVISE-PPF results, an innovation hub session on real-world use, and an exhibition of the technology are planned. By converting clinical validation and strategic pharma collaboration into broader U.S. adoption, Brainomix is seeking to leverage e-Lung’s CT biomarker capabilities as a commercial and strategic growth driver alongside its stroke imaging platform, with potential implications for future partnerships, reimbursement discussions, and expansion beyond its current operations in more than 20 countries.